|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZC3HC1 |
Gene summary for ZC3HC1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZC3HC1 | Gene ID | 51530 |
| Gene name | zinc finger C3HC-type containing 1 | |
| Gene Alias | HSPC216 | |
| Cytomap | 7q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q86WB0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51530 | ZC3HC1 | LZE4T | Human | Esophagus | ESCC | 1.51e-06 | 1.25e-01 | 0.0811 |
| 51530 | ZC3HC1 | LZE24T | Human | Esophagus | ESCC | 1.77e-07 | 1.37e-01 | 0.0596 |
| 51530 | ZC3HC1 | P2T-E | Human | Esophagus | ESCC | 4.77e-07 | 1.52e-01 | 0.1177 |
| 51530 | ZC3HC1 | P4T-E | Human | Esophagus | ESCC | 8.50e-17 | 3.48e-01 | 0.1323 |
| 51530 | ZC3HC1 | P5T-E | Human | Esophagus | ESCC | 1.58e-05 | 1.29e-01 | 0.1327 |
| 51530 | ZC3HC1 | P8T-E | Human | Esophagus | ESCC | 5.97e-12 | 1.26e-01 | 0.0889 |
| 51530 | ZC3HC1 | P9T-E | Human | Esophagus | ESCC | 1.33e-04 | 1.29e-01 | 0.1131 |
| 51530 | ZC3HC1 | P10T-E | Human | Esophagus | ESCC | 2.60e-13 | 1.86e-01 | 0.116 |
| 51530 | ZC3HC1 | P11T-E | Human | Esophagus | ESCC | 9.04e-07 | 1.66e-01 | 0.1426 |
| 51530 | ZC3HC1 | P12T-E | Human | Esophagus | ESCC | 2.57e-20 | 3.40e-01 | 0.1122 |
| 51530 | ZC3HC1 | P15T-E | Human | Esophagus | ESCC | 5.58e-25 | 4.50e-01 | 0.1149 |
| 51530 | ZC3HC1 | P16T-E | Human | Esophagus | ESCC | 2.48e-11 | 1.72e-01 | 0.1153 |
| 51530 | ZC3HC1 | P17T-E | Human | Esophagus | ESCC | 2.15e-02 | 1.64e-01 | 0.1278 |
| 51530 | ZC3HC1 | P20T-E | Human | Esophagus | ESCC | 1.03e-09 | 1.26e-01 | 0.1124 |
| 51530 | ZC3HC1 | P21T-E | Human | Esophagus | ESCC | 1.37e-10 | 2.30e-01 | 0.1617 |
| 51530 | ZC3HC1 | P22T-E | Human | Esophagus | ESCC | 7.84e-06 | 7.14e-02 | 0.1236 |
| 51530 | ZC3HC1 | P23T-E | Human | Esophagus | ESCC | 8.80e-11 | 1.22e-01 | 0.108 |
| 51530 | ZC3HC1 | P24T-E | Human | Esophagus | ESCC | 1.11e-08 | 2.09e-01 | 0.1287 |
| 51530 | ZC3HC1 | P26T-E | Human | Esophagus | ESCC | 9.28e-14 | 2.47e-01 | 0.1276 |
| 51530 | ZC3HC1 | P27T-E | Human | Esophagus | ESCC | 1.80e-15 | 2.42e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:2001233111 | Esophagus | ESCC | regulation of apoptotic signaling pathway | 256/8552 | 356/18723 | 4.11e-24 | 1.04e-21 | 256 |
| GO:0097191111 | Esophagus | ESCC | extrinsic apoptotic signaling pathway | 159/8552 | 219/18723 | 4.12e-16 | 2.94e-14 | 159 |
| GO:2001234111 | Esophagus | ESCC | negative regulation of apoptotic signaling pathway | 161/8552 | 224/18723 | 1.24e-15 | 8.09e-14 | 161 |
| GO:2001236111 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway | 111/8552 | 151/18723 | 2.97e-12 | 1.18e-10 | 111 |
| GO:2001237111 | Esophagus | ESCC | negative regulation of extrinsic apoptotic signaling pathway | 69/8552 | 97/18723 | 3.23e-07 | 4.55e-06 | 69 |
| GO:00380347 | Esophagus | ESCC | signal transduction in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
| GO:00971927 | Esophagus | ESCC | extrinsic apoptotic signaling pathway in absence of ligand | 48/8552 | 65/18723 | 3.63e-06 | 3.97e-05 | 48 |
| GO:20012394 | Esophagus | ESCC | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
| GO:19010992 | Esophagus | ESCC | negative regulation of signal transduction in absence of ligand | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
| GO:20012402 | Esophagus | ESCC | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
| GO:200123322 | Liver | HCC | regulation of apoptotic signaling pathway | 226/7958 | 356/18723 | 7.26e-16 | 5.68e-14 | 226 |
| GO:009719122 | Liver | HCC | extrinsic apoptotic signaling pathway | 143/7958 | 219/18723 | 6.99e-12 | 2.97e-10 | 143 |
| GO:200123412 | Liver | HCC | negative regulation of apoptotic signaling pathway | 145/7958 | 224/18723 | 1.33e-11 | 5.36e-10 | 145 |
| GO:200123621 | Liver | HCC | regulation of extrinsic apoptotic signaling pathway | 98/7958 | 151/18723 | 2.17e-08 | 5.08e-07 | 98 |
| GO:200123712 | Liver | HCC | negative regulation of extrinsic apoptotic signaling pathway | 62/7958 | 97/18723 | 1.67e-05 | 1.81e-04 | 62 |
| GO:200123320 | Oral cavity | OSCC | regulation of apoptotic signaling pathway | 242/7305 | 356/18723 | 6.66e-29 | 3.24e-26 | 242 |
| GO:200123420 | Oral cavity | OSCC | negative regulation of apoptotic signaling pathway | 148/7305 | 224/18723 | 1.71e-16 | 1.36e-14 | 148 |
| GO:009719120 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway | 142/7305 | 219/18723 | 7.34e-15 | 4.55e-13 | 142 |
| GO:200123620 | Oral cavity | OSCC | regulation of extrinsic apoptotic signaling pathway | 100/7305 | 151/18723 | 1.07e-11 | 3.90e-10 | 100 |
| GO:00380346 | Oral cavity | OSCC | signal transduction in absence of ligand | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZC3HC1 | SNV | Missense_Mutation | c.242N>A | p.Arg81Lys | p.R81K | Q86WB0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR | |
| ZC3HC1 | SNV | Missense_Mutation | c.634N>C | p.Asp212His | p.D212H | Q86WB0 | protein_coding | deleterious(0) | probably_damaging(0.923) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZC3HC1 | SNV | Missense_Mutation | c.941N>T | p.Arg314Leu | p.R314L | Q86WB0 | protein_coding | deleterious(0.01) | possibly_damaging(0.458) | TCGA-D8-A27N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol+adriamycin+cyclophosphamide+herceptin | SD | |
| ZC3HC1 | insertion | In_Frame_Ins | novel | c.866_867insATTATCTCCCCTTTCCTTCAGGCTGAAAAGAGCCCTGGT | p.Ser289_Ser290insLeuSerProLeuSerPheArgLeuLysArgAlaLeuVal | p.S289_S290insLSPLSFRLKRALV | Q86WB0 | protein_coding | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | ||
| ZC3HC1 | SNV | Missense_Mutation | c.242N>C | p.Arg81Thr | p.R81T | Q86WB0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZC3HC1 | SNV | Missense_Mutation | novel | c.293N>G | p.Ser98Cys | p.S98C | Q86WB0 | protein_coding | deleterious(0.04) | possibly_damaging(0.729) | TCGA-VS-A8EI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZC3HC1 | SNV | Missense_Mutation | novel | c.1181N>G | p.Ser394Cys | p.S394C | Q86WB0 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| ZC3HC1 | SNV | Missense_Mutation | c.227N>T | p.Glu76Val | p.E76V | Q86WB0 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-AA-3860-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | folinic | CR | |
| ZC3HC1 | SNV | Missense_Mutation | novel | c.934C>T | p.Pro312Ser | p.P312S | Q86WB0 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZC3HC1 | SNV | Missense_Mutation | c.1082N>C | p.Val361Ala | p.V361A | Q86WB0 | protein_coding | tolerated(0.19) | benign(0.009) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |